Lead Product(s) : INF904
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
InflaRx Announces Positive Topline Results from Phase I Study with C5aR Inhibitor INF904
Details : INF904 is an orally administered low molecular weight C5aR inhibitor which is under phase 1 clinical development for the treatment of inflammatory diseases.
Product Name : INF904
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2024
Lead Product(s) : INF904
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : INF904
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : INF904 is an orally administered small molecule inhibitor of C5a-induced signaling via the receptor C5aR, which is investigated for the treatment of inflammatory diseases.
Product Name : INF904
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 09, 2023
Lead Product(s) : INF904
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Povetacicept
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Alpine Immune Sciences
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Details : The programme includes upstream and downstream process, analytical method, and formulation development with a view to support commercial manufacturing of ALPN 303.
Product Name : ALPN-303
Product Type : Protein
Upfront Cash : Undisclosed
October 08, 2022
Lead Product(s) : Povetacicept
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Alpine Immune Sciences
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Lead Product(s) : INF904
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
InflaRx Initiates First-in-Human Study with Small Molecule C5aR Inhibitor INF904
Details : INF904 showed anti-inflammatory therapeutic effects in several preclinical disease models and there were no obvious toxicological findings in investigational new drug (IND)-enabling (preclinical) studies, including required good laboratory practice (GLP)...
Product Name : INF904
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 11, 2022
Lead Product(s) : INF904
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Grünenthal's Glucocorticoid Receptor Modulator Enters Clinical Development
Details : Phase III studies investigating efficacy, safety and tolerability of Qutenza (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP) and the efficacy, safety and tolerability of Resiniferatoxin in patients with pain associated with osteoar...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 27, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sonelokimab
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : MoonLake Immunotherapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
MoonLake Immunotherapeutics Licensed Tri-Specific Nanobody® Sonelokimab from Merck KGaA
Details : MoonLake Immunotherapeutics plans to accelerate the development of Sonelokimab in multiple inflammatory diseases in dermatology and rheumatology driven by IL-17A and IL-17F.
Product Name : M1095
Product Type : Antibody
Upfront Cash : Undisclosed
March 05, 2021
Lead Product(s) : Sonelokimab
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : MoonLake Immunotherapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : MIC-Lx
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TolerogenixX Reports Positive Phase Ib Data of its Lead Product to Combat Transplant Rejection
Details : The so-called TOL-1 study met all endpoints and demonstrated the feasibility and safety of MIC-Lx administration in inducing donor-specific tolerance in kidney transplant recipients.
Product Name : MIC-Lx
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 05, 2020
Lead Product(s) : MIC-Lx
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable